Literature DB >> 28315675

Low-Intensity Training and the C5a Complement Antagonist NOX-D21 Rescue the mdx Phenotype through Modulation of Inflammation.

Janek Hyzewicz1, Jun Tanihata1, Mutsuki Kuraoka1, Yuko Nitahara-Kasahara1, Teiva Beylier1, Urs T Ruegg2, Axel Vater3, Shin'ichi Takeda4.   

Abstract

Inflammatory events occurring in dystrophic muscles contribute to the progression of Duchenne muscular dystrophy (DMD). Low-intensity training (LIT) attenuates the phenotype of mdx mice, an animal model for DMD. Therefore, we postulated that LIT could have anti-inflammatory properties. We assessed levels of inflammatory cytokines and infiltrated immune cells in gastrocnemius muscle of mdx mice after LIT. We detected high levels of complement component C5a, chemokine ligand (CCL) 2, CD68+ monocytes/macrophages, and proinflammatory M1 macrophages in muscles of mdx mice. LIT decreased CCL2 levels, increased CD68+ cell numbers, and shifted the macrophage population to the regenerative M2 type. We investigated whether inhibition of C5a or CCL2 with L-aptamers could mimic the effects of LIT. Although no effect of CCL2 inhibition was detected, treatment with the C5a inhibitor, NOX-D21, rescued the phenotype of nonexercised mdx mice, but not of exercised ones. In both cases, the level of CD68+ cells increased and macrophage populations leaned toward the inflammatory M1 type. In muscles of nonexercised treated mice, the level of IL-1 receptor antagonist increased, damage decreased, and fibers were switched toward the glycolytic fast type; in muscles of exercised mice, fibers were switched to the oxidative slow type. These results reveal the effects of LIT on the inflammatory status of mdx mice and suggest that NOX-D21 could be an anti-inflammatory drug for DMD.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28315675     DOI: 10.1016/j.ajpath.2016.12.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  7 in total

Review 1.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

2.  Low-intensity training provokes adaptive extracellular matrix turnover of a muscular dystrophy model.

Authors:  Thaís P Gaiad; Murilo X Oliveira; Adalfredo R Lobo; Lívia R Libório; Priscilla A F Pinto; Danielle C Fernandes; Ana Paula Santos; Carlos Eduardo Ambrósio; Alex Sander D Machado
Journal:  J Exerc Rehabil       Date:  2017-12-27

Review 3.  Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies.

Authors:  Ahlke Heydemann
Journal:  Nutrients       Date:  2018-06-20       Impact factor: 5.717

4.  Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy.

Authors:  Yuko Nitahara-Kasahara; Mutsuki Kuraoka; Posadas Herrera Guillermo; Hiromi Hayashita-Kinoh; Yasunobu Maruoka; Aki Nakamura-Takahasi; Koichi Kimura; Shin'ichi Takeda; Takashi Okada
Journal:  Stem Cell Res Ther       Date:  2021-01-25       Impact factor: 6.832

5.  Twenty-one days of low-intensity eccentric training improve morphological characteristics and function of soleus muscles of mdx mice.

Authors:  Paulo S Pedrazzani; Tatiana O P Araújo; Emilly Sigoli; Isabella R da Silva; Daiane Leite da Roza; Deise Lucia Chesca; Dilson E Rassier; Anabelle S Cornachione
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

6.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice.

Authors:  Yasunari Matsuzaka; Jun Tanihata; Yoshiko Ooshima; Daisuke Yamada; Masayuki Sekiguchi; Shouta Miyatake; Yoshitsugu Aoki; Mika Terumitsu; Ryu Yashiro; Hirofumi Komaki; Akihiko Ishiyama; Yasushi Oya; Yukiko U Inoue; Takayoshi Inoue; Shin'ichi Takeda; Kazuo Hashido
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.